TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31964340

Group type: COMPARATOR
Intervention: Internal fixation (IF)
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1440
Study: 30561610

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly subcutaneous injection
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 28124736

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC) at 2 L/kg/min oxygen therapy
Number of subjects: 142

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP) at 7 cmH2O
Number of subjects: 142
Study: 26103129

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4 g daily for 8 weeks)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Coenzyme Q10 (200 mg daily for 8 weeks)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (4 g olive oil daily for 8 weeks)
Number of subjects: 74
Study: 25386520

Group type: EXPERIMENTAL
Intervention: SRP and locally delivered propolis
Number of subjects: 20

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 20
Study: 20236716

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg/d)
Number of subjects: 42
Study: 19268686

Group type: EXPERIMENTAL
Intervention: 5 microg TTX
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 10 microg TTX
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 17106937

Group type: EXPERIMENTAL
Intervention: 9 mug CIFN three times per week for 52 wk plus ribavirin 800 to 1200 mg daily for 52 wk
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 18 mug CIFN three times per week for 52 wk plus ribavirin 800 to 1200 mg daily for 52 wk
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CIFN in combination with ribavirin (both doses)
Number of subjects: 45

Group type: COMPARATOR
Intervention: CIFN in combination with ribavirin
Number of subjects: 45
Study: 14702423

Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg once daily
Number of subjects: 1484

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1484
Study: 11724461

Group type: EXPERIMENTAL
Intervention: Dietary treatment (specific dietary fatty acids not detailed)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Higher birth weight
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Day 5 plasma 22:5n-6
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Day 5 red cell membrane 20:3n-9
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Number of smokers in the household
Number of subjects: 185
Study: 9215816

Group type: EXPERIMENTAL
Intervention: Preoperative doxorubicin and cyclophosphamide (AC)
Number of subjects: 1523
Study: 8020175

Group type: EXPERIMENTAL
Intervention: Prophylactic ceftriaxone administration (Group A)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Therapeutical application of ceftriaxone (Group B)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Other antibiotics (Group C)
Number of subjects: 303

Group type: COMPARATOR
Intervention: No antibiotics (Group D)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Prophylactic ceftriaxone administration (Group A) - Newborns
Number of subjects: 303

Group type: COMPARATOR
Intervention: Therapeutical application of ceftriaxone (Group B) - Newborns
Number of subjects: 303
Study: 3300977

Group type: EXPERIMENTAL
Intervention: Isosorbide 5-mononitrate 20 mg (3 X 20 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide 5-mononitrate 50 mg (once daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg (3 X 20 mg/day)
Number of subjects: 12
Study: 28117541

Group type: EXPERIMENTAL
Intervention: Two sessions of skills assessment with feedback (group B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Two sessions of additional skills training (group A)
Number of subjects: 32
Study: 27059970

Group type: EXPERIMENTAL
Intervention: Modified stents for 3 days (Group A)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Modified stents for 2 days (Group B)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Balloon dilation (Group C)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Regular stents for 2 days (Group D)
Number of subjects: 77
Study: 24102964

Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (10 μg/kg per min)
Number of subjects: 56
Study: 22427290

Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison between Cinnarizine and Propranolol
Number of subjects: 120
Study: 21953602

Group type: EXPERIMENTAL
Intervention: Acute cortisol (30 mg hydrocortisone)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18310602

Group type: EXPERIMENTAL
Intervention: Cinacalcet combined with low doses of vitamin D sterols
Number of subjects: 444

Group type: COMPARATOR
Intervention: Cinacalcet alone
Number of subjects: 444
Study: 17323592

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus Aspirin (dual antiplatelet therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (monotherapy)
Number of subjects: 0
Study: 12891166

Group type: EXPERIMENTAL
Intervention: Regular exercise as part of cardiac rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graded conditioning program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise rehabilitation
Number of subjects: 0
Study: 10923282

Group type: EXPERIMENTAL
Intervention: Drospirenone alone (0.5-3.0 mg/day for one cycle)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (30 micrograms) + Drospirenone (2 mg or 3 mg for three cycles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (30 micrograms) + Drospirenone (3 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethinylestradiol (30 micrograms) + Desogestrel (150 micrograms) (Marvelon)
Number of subjects: 0
Study: 8828991

Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg
Number of subjects: 20
Study: 1424207

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a dosage of 1.2 IU/kg/week for 18 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 22
Study: 4096058

Group type: EXPERIMENTAL
Intervention: Conditioned by situation 'consulting hours hypertension'
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Haemodynamically oriented differential therapy
Number of subjects: 84
Study: 30293411

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (2000 single shocks; strength, 1.5 to 3.0 bar; shock frequency, 9 to 12 Hz)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Physical treatments (acupuncture, ultrasonic wave, microwave therapy)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Between-groups comparison
Number of subjects: 51
Study: 30134289

Group type: EXPERIMENTAL
Intervention: RAL-based regimen for 10 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuation of nonintegrase inhibitor regimen
Number of subjects: 40
Study: 28096711

Group type: EXPERIMENTAL
Intervention: High Intensity Laser Therapy (HILT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham Laser
Number of subjects: 72
Study: 24356594

Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy (INT)
Number of subjects: 1441
Study: 22883020

Group type: EXPERIMENTAL
Intervention: Sevoflurane using the anesthetic-conserving device (ACD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous sedation with propofol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane using the ACD
Number of subjects: 0
Study: 20308973

Group type: EXPERIMENTAL
Intervention: Rhodiola Rosea
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 17986941

Group type: EXPERIMENTAL
Intervention: Supine position for 3 days after burr-hole surgery (Group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sitting position with head of bed elevated to 30 to 40 degrees for 3 days after burr-hole surgery (Group B)
Number of subjects: 84
Study: 15206003

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at a mean dose of 0.25‐0.3 mg/kg body weight
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 99
Study: 11773299

Group type: EXPERIMENTAL
Intervention: Paclitaxel-based adjuvant chemotherapy
Number of subjects: 6754

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) or anthracycline-based regimens
Number of subjects: 6754
Study: 9649976

Group type: EXPERIMENTAL
Intervention: 5-day lofexidine treatment
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 10-day lofexidine treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Methadone treatment
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both lofexidine regimens
Number of subjects: 61

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 61
Study: 7972809

Group type: EXPERIMENTAL
Intervention: Renal duplex Doppler sonography
Number of subjects: 32
Study: 2637078

Group type: EXPERIMENTAL
Intervention: 1.5 x 5 Gy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2.15 x 2 Gy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3.5 x 2.5 Gy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 5 x 5 Gy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Preoperative radiation (general)
Number of subjects: 90
Study: 1095162

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 30
Study: 31801584

Group type: EXPERIMENTAL
Intervention: Upgraded maternity waiting homes (MWHs) + religious/community leader training
Number of subjects: 3840

Group type: EXPERIMENTAL
Intervention: Leader training alone
Number of subjects: 3840

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3840
Study: 28268215

Group type: EXPERIMENTAL
Intervention: Buprenorphine oral lyophilisate (bup-lyo)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Buprenorphine sublingual tablets (bup-SL)
Number of subjects: 36
Study: 26051445

Group type: EXPERIMENTAL
Intervention: Conventional Resistance Training (CRT)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training (WBVT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard Follow-up (CON)
Number of subjects: 121
Study: 23224689

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 21708823

Group type: EXPERIMENTAL
Intervention: Resistance exercise for 8 weeks
Number of subjects: 19
Study: 19349387

Group type: EXPERIMENTAL
Intervention: CRE-led management
Number of subjects: 198

Group type: COMPARATOR
Intervention: MD-managed patients
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Composite analysis of both CRE and MD data
Number of subjects: 198
Study: 16765759

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation therapy (target international normalised ratio of 2.0-3.0)
Number of subjects: 6706

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg per day) plus aspirin (75-100 mg per day)
Number of subjects: 6706

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation therapy (for patients already receiving treatment at study entry)
Number of subjects: 6706

Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin (for patients not on oral anticoagulation therapy at study entry)
Number of subjects: 6706
Study: 15604228

Group type: EXPERIMENTAL
Intervention: Cooperative Family Learning Approach (CFLA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11895463

Group type: EXPERIMENTAL
Intervention: Intracoronary treatment with oestrogen (group 2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No intracoronary treatment (group 1)
Number of subjects: 24
Study: 10102427

Group type: EXPERIMENTAL
Intervention: 4.5 million international units (mIU) of IFN‐alpha2a
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 9.0 million international units (mIU) of IFN‐alpha2a
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: IFN‐alpha2a treatment
Number of subjects: 97
Study: 7775507

Group type: EXPERIMENTAL
Intervention: SkinTemp dressing (covered for 7 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Xeroform dressing (covered for 24 hours)
Number of subjects: 8
Study: 2290737

Group type: EXPERIMENTAL
Intervention: Cooperative Care Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual hospitalization
Number of subjects: 0
Study: 363490

Group type: EXPERIMENTAL
Intervention: Sulfonylurea or insulin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral glucose load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Successful treatment with sulfonylurea or insulin
Number of subjects: 0
Study: 31831167

Group type: EXPERIMENTAL
Intervention: Palliative care educational video
Number of subjects: 111

Group type: COMPARATOR
Intervention: Non‐directive cancer center video
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Palliative care services utilization (historical data)
Number of subjects: 111
Study: 30400757

Group type: EXPERIMENTAL
Intervention: Group Stepping Stones Triple P (GSSTP)
Number of subjects: 8
Study: 28079621

Group type: EXPERIMENTAL
Intervention: Additional education by the IBD nurse with an information brochure and vaccination card
Number of subjects: 505

Group type: COMPARATOR
Intervention: Routine clinical practice
Number of subjects: 505
Study: 26067585

Group type: EXPERIMENTAL
Intervention: ABT-639 (100 mg twice daily)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg twice daily)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 23629145

Group type: EXPERIMENTAL
Intervention: Conventional diet or meal replacements
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Caregivers lost above the median (‐1.67%) at month 4
Number of subjects: 113
Study: 21427652

Group type: EXPERIMENTAL
Intervention: Taprostene
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 19995115

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 17241414

Group type: EXPERIMENTAL
Intervention: BOTOX (50 U)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dysport (150 U)
Number of subjects: 10
Study: 15493734

Group type: EXPERIMENTAL
Intervention: Premature infant formula
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard term infant formula
Number of subjects: 34
Study: 11447547

Group type: EXPERIMENTAL
Intervention: Tourniquet use during surgery (T)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No tourniquet use during surgery (NT)
Number of subjects: 48
Study: 9756585

Group type: EXPERIMENTAL
Intervention: Selective intra-arterial fibrinolysis with Urokinase (100,000 to 900,000 IU) administered over 10 to 90 minutes
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no fibrinolytics)
Number of subjects: 17
Study: 7846309

Group type: EXPERIMENTAL
Intervention: Low-dose group (400 mg of soil/day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-dose group (2.0 g of soil/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 9
Study: 2898400

Group type: EXPERIMENTAL
Intervention: Iron dextran (Imferon) administered by total dose infusion (TDI) at high dose
Number of subjects: 623

Group type: COMPARATOR
Intervention: Iron dextran (Imferon) administered by total dose infusion (TDI) at low dose
Number of subjects: 623
Study: 31452382

Group type: EXPERIMENTAL
Intervention: Concomitant treatments for non-communicable diseases (NCD)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Baseline frequency of comorbidities
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Last visit frequency of comorbidities
Number of subjects: 451
Study: 27956737

Group type: EXPERIMENTAL
Intervention: Aspartame-sweetened beverage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Monk fruit-sweetened beverage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Stevia-sweetened beverage
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sucrose-sweetened beverage
Number of subjects: 30
Study: 25225010

Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy (three courses)
Number of subjects: 35
Study: 23470571

Group type: EXPERIMENTAL
Intervention: Neurectomy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 44
Study: 21172596

Group type: EXPERIMENTAL
Intervention: Echocardiography interpretation by local lab
Number of subjects: 199
Study: 19100967

Group type: COMPARATOR
Intervention: ADHD‐HI
Number of subjects: 197

Group type: COMPARATOR
Intervention: ADHD‐C
Number of subjects: 197

Group type: COMPARATOR
Intervention: ADHD‐I
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 197
Study: 17059933

Group type: EXPERIMENTAL
Intervention: Papaverine injection into the endothoracic fascia (Group 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation (Group 3)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of papaverine and carbon dioxide (Group 4)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No vasodilatory management (Group 1)
Number of subjects: 100
Study: 15222594

Group type: EXPERIMENTAL
Intervention: Day Hospital (DH) program for 3 weeks
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Community-based program (CP2) for 4 weeks
Number of subjects: 271

Group type: COMPARATOR
Intervention: Community-based program (CP1) for 6 weeks
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Day Hospital (DH) program
Number of subjects: 271

Group type: COMPARATOR
Intervention: Community-based program (CP1)
Number of subjects: 271
Study: 10778374

Group type: EXPERIMENTAL
Intervention: Active management of labor protocol
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control protocol
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Active management of labor protocol (for cesarean sections)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control protocol (for cesarean sections)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Active management of labor protocol (for spontaneous vaginal deliveries)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control protocol (for spontaneous vaginal deliveries)
Number of subjects: 405
Study: 9324179

Group type: EXPERIMENTAL
Intervention: Ketorolac by PCA bolus alone (Ket B)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Ketorolac by bolus plus infusion (Ket I)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Morphine by PCA bolus (morphine)
Number of subjects: 191
Study: 8269450

Group type: EXPERIMENTAL
Intervention: Dinoprostone cervical gel 0.5 mg administered 12 hours prior to oxytocin induction
Number of subjects: 514

Group type: COMPARATOR
Intervention: Control group (observed during the same period)
Number of subjects: 514
Study: 3517967

Group type: EXPERIMENTAL
Intervention: Memantine 20-30mg intravenously
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 20
Study: 31300303

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Digital hearing aids
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 and hearing aids
Number of subjects: 33
Study: 29813147

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 858

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg and 240 mg
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 858
Study: 27160898

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intravenous glucagon infusion
Number of subjects: 9
Study: 23983090

Group type: EXPERIMENTAL
Intervention: TENS and knee group (n = 73)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Sham TENS and knee group (n = 74)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Knee group (n = 77)
Number of subjects: 224
Study: 22343180

Group type: EXPERIMENTAL
Intervention: Shang Ring removal at 7 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Shang Ring removal at 14 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Shang Ring removal at 21 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Shang Ring (all groups)
Number of subjects: 50
Study: 19727794

Group type: EXPERIMENTAL
Intervention: ICare rebound tonometer (RT)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Both tonometers (RT and GAT)
Number of subjects: 327
Study: 18729781

Group type: EXPERIMENTAL
Intervention: Repeated doses of albendazole over 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not treated (Control)
Number of subjects: 0
Study: 15948265

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (66 Gy)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Preoperative radiotherapy (50 Gy)
Number of subjects: 129
Study: 12362957

Group type: EXPERIMENTAL
Intervention: 2-phase cognitive-behavioral treatment (Phase 1: 8 weekly sessions of skills training in affect and interpersonal regulation; Phase 2: 8 sessions of modified prolonged exposure)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 2-phase cognitive-behavioral treatment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Phase 1 therapeutic alliance and negative mood regulation skills
Number of subjects: 58

Group type: COMPARATOR
Intervention: minimal attention wait list
Number of subjects: 58
Study: 11208622

Group type: EXPERIMENTAL
Intervention: Budesonide 2,400 microg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9622147

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 2955

Group type: EXPERIMENTAL
Intervention: Irbesartan (dose range 1 to 900 mg)
Number of subjects: 2955

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2955